findmyKOL

Michel Kuzur, MD

Basic profile

Sarah Cannon

ORCIDNone on fileNPI
RegionNashville, TN · SoutheastSpecialtyMedical OncologyFocusOncology
Last active 2017findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2017Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Michel Kuzur is an Oncology physician affiliated with Sarah Cannon. OpenAlex indexes 11 publications with 285 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
11publications

Distinct works indexed by OpenAlex.

285citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

1 company with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    95.4%
    Iron, parenteral preparations52.3%
    Ferric carboxymaltose100%
    Part B, office-administered15 patients
    Erythropoiesis-stimulating Agent43%
    Darbepoetin alfa100%
    Part B, office-administered22 patients

    + 2 more classes in this area

  • Sensory organs

    3.7%
    Corticosteroid3.7%
    Dexamethasone sodium phosphate99%Dexamethasone1%
    Part D + Part B<11 patients
  • Cancer & immunology

    0.4%
    Aromatase Inhibitor0.2%
    Anastrozole100%
    Part D17 patients
    Kinase inhibitor0.2%
    Imbruvica33%Calquence30%Ibrance19%Jakafi17%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)0.2% facility · 99.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”